Medical specialists from France tagged as investigators in clinical trials studying Melanoma

Total 278 results

A Essemilaire, MD
Seen in:
- Nancy, Chu de Nancy
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Adeline Finet, MD
Seen in:
- Boulogne-Billancourt, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Agnès DUCOULOMBIER, MD
Seen in:
- Nice, Centre Antoine Lacassagne
Trials:
- NCT05588700 (Principal Investigator)
- NCT04728113 (Principal Investigator)
Conditions:
- Metastatic Testicular Cancer;
- Uveal Melanoma
Alain Bonnin, MD, PhD
Seen in:
- Dijon, CHU de Dijon
Trials:
- NCT02828202 (Principal Investigator)
Conditions:
- Malignant Melanoma
Alain Dupuy, MD, PhD
Seen in:
- Rennes, CHU de Rennes
Trials:
- NCT02828202 (Principal Investigator)
Conditions:
- Malignant Melanoma
Alexandra Picard, MD
Seen in:
- Nice, CHU de Nice
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Alexandra Traverse-Glehen, MD, PhD
Seen in:
- Lyon, Hospices Civils de Lyon
Trials:
- NCT02828202 (Principal Investigator)
Conditions:
- Malignant Melanoma
Alice Hervieu, Dr.
Seen in:
- Dijon, CHU de Dijon - Centre Georges-Francois-Leclerc
- Dijon, Centre Georges Francois Leclerc
- Dijon, Service d'Oncologie Médicale -Centre Georges François LECLERC
Trials:
- NCT03235245 (Principal Investigator)
- NCT05155254 (Principal Investigator)
- NCT02389244 (Principal Investigator)
- NCT06081400 (Principal Investigator)
Conditions:
Alice Viarnaud, MD
Seen in:
- Créteil, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Amandine BRUYAS, MD
Seen in:
- Pierre-Bénite, Centre Hospitalier Lyon Sud - Department of Medical Oncology
Trials:
- NCT04605146 (Sub-Investigator)
Conditions:
- Melanoma;
- Lung Cancer;
- Renal Cancer
Amelie Gantzer, MD
Seen in:
- Boulogne-Billancourt, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Andrea Cavalcanti
Seen in:
- Paris, Institut Gustave Roussy
Trials:
- NCT01942603 (Principal Investigator)
Conditions:
- Cutaneous Melanoma
Anna Greliak, MD
Seen in:
- Lille, CHRU de Lille
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Anne-Claire Bing, MD
Seen in:
- Annecy, Ch Annecy Genevois
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Anne-Marie Dupuy, MD
Seen in:
- Montpellier, CHU de Montpellier
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Anne-Sophie Bertrand, MD
Seen in:
- Montpellier, CHU de Montpellier
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Anouck Lamoureux, MD
Seen in:
- Montpellier, CHU de Montpellier
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Antoine Italiano, MD
Seen in:
- Bordeaux, Institut Bergonie
- Bordeaux, Institute Bergonie
Trials:
- NCT03767348 (Principal Investigator)
- NCT02389244 (Principal Investigator)
- NCT05480865 (Principal Investigator)
- NCT02638766 (Principal Investigator)
Conditions:
Antonie Italiano, MD
Seen in:
- Bordeaux, Institut Bergonie
Trials:
- NCT04913285 (Principal Investigator)
Conditions:
Antonin FATTORI
Seen in:
- Strasbourg, Les Hôpitaux Universitaires de Strasbourg
Trials:
- NCT05089188 (Sub-Investigator)
Conditions:
- Melanoma
Arnaud Jannic, MD
Seen in:
- Créteil, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Astrid Blom, MD
Seen in:
- Boulogne-Billancourt, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Barouyr BAROUDJIAN
Seen in:
- Paris, APHP-Saint Louis
- Paris, Assistance Publique - Hôpitaux de Paris (AP-HP), Hopital Saint-Louis, centre d'oncodermatologie
Trials:
- NCT05429138 (Sub-Investigator)
- NCT02828202 (Sub-Investigator)
Conditions:
- Melanoma;
- Malignant Melanoma
Beatrice Vergier, MD, PhD
Seen in:
- Bordeaux, CHU de Bordeaux Hôpital Saint-André
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Beatrice Villette, MD
Seen in:
- Bobigny, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Avicennes
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma
Bénédicte OULES
Seen in:
- Paris, APHP-Cochin
Trials:
- NCT05429138 (Sub-Investigator)
Conditions:
- Melanoma
Benoit YOU, MD
Seen in:
- Pierre-Bénite, Centre Hospitalier Lyon Sud - Department of Medical Oncology
- Pierre-Bénite, Service de Médecine du vieillissement, Centre Hospitalier Lyon Sud (Hospices Civils de Lyon)
Trials:
- NCT03296150 (Sub-Investigator)
- NCT04605146 (Sub-Investigator)
Conditions:
- Cancer;
- Oral Anticancer Drugs;
- Melanoma;
- Lung Cancer;
- Renal Cancer
Bertille Bonniaud, MD
Seen in:
- Dijon, CHU de Dijon
Trials:
- NCT02828202 (Sub-Investigator)
Conditions:
- Malignant Melanoma

Clinical Trials on Melanoma

H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
MelanomaPRO, Russia

Recruiting

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (ISABELLA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, Ocular

Russian Federation
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC Melanoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); University of Virginia

Completed

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Emory University
Genentech, Inc.

Active, not recruiting

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IV

United States
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus

Medical specialists from France tagged as investigators in clinical trials studying Melanoma

Clinical Trials on Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations